Overview
Clinical Study of 68Ga Labeled HER2 Affibody Analogues
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily evaluate its diagnosis value in patients with breast or gastric tumors.Phase:
Early Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Xijing Hospital
Criteria
Inclusion Criteria:- patients with breast or gastric cancers: diagnosed by MR and ready for surgery
Exclusion Criteria:
- refuse or cannot endure surgery pregnant women